Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vanda Pharmaceuticals Inc VNDA

Healthcare Biotechnology
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in... see more

Recent & Breaking News (NDAQ:VNDA)

Vanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024

PR Newswire July 26, 2024

Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex

PR Newswire July 1, 2024

Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders

PR Newswire June 19, 2024

Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak

PR Newswire June 13, 2024

Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.

Business Wire June 10, 2024

Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd.

PR Newswire June 6, 2024

Vanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare Conference

PR Newswire May 30, 2024

Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY®

PR Newswire May 30, 2024

Vanda Pharmaceuticals Announces Presentations at SLEEP 2024

PR Newswire May 29, 2024

Vanda Pharmaceuticals Board of Directors Determines that Revised Unsolicited Takeover Proposal is Not in the Best Interests of the Company and its Shareholders

PR Newswire May 24, 2024

Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness

PR Newswire May 15, 2024

Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results

PR Newswire May 8, 2024

Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak

PR Newswire May 7, 2024

Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024

PR Newswire April 30, 2024

Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation

PR Newswire April 22, 2024

Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan

PR Newswire April 17, 2024

Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak

PR Newswire April 17, 2024

Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder

PR Newswire April 2, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA

Newsfile March 29, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA

PR Newswire March 27, 2024